Association between gene expression signatures and clinical outcomes of pembrolizumab versus paclitaxel in advanced gastric cancer: exploratory analysis from the randomized, controlled, phase III KEYNOTE-061 trial

By sjmartinez • July 4, 2023

Shitara K, Di Bartolomeo M, Mandala M, Ryu MH, Caglevic C, Olesinski T, Chung HC, Muro K, Goekkurt E, McDermott RS, Mansoor W, Wainberg ZA, Shih CS, Kobie J, Nebozhyn M, Cristescu R, Cao ZA, Loboda A, Özgüroğlu M. Association between gene expression signatures and clinical outcomes of pembrolizumab versus paclitaxel in advanced gastric cancer: exploratory analysis from the randomized, controlled, phase III KEYNOTE-061 trial. J Immunother Cancer. 2023 Jun;11(6):e006920. doi: 10.1136/jitc-2023-006920. PMID: 37399357; PMCID: PMC10314681.

Tags: Gastrointestinal neoplasms, Gene Expression Profiling, Genetic Markers, Hematology/Oncology, immunotherapy, Programmed Cell Death 1 Receptor, Publications

A phase 1 safety and feasibility trial of a ketogenic diet plus standard of care for patients with recently diagnosed glioblastoma

Amaral LJ, Gresham G, Kim S, Tighiouart M, Nelson TA, Welborn A, Lockshon L, Noorvash B, Rudnick JD, Irwin SA, Freedland SJ, Hu J. A[...]

Human cancer-targeted immunity via transgenic hematopoietic stem cell progeny

Nowicki TS, Deen NNA, Peters CW, Comin-Anduix B, Medina E, Puig-Saus C, Carretero IB, Kaplan-Lefko P, Macabali MH, Garcilazo IP, Chen D, Pang J, Berent-Maoz[...]

Rucaparib for maintenance treatment of platinum-sensitive, recurrent ovarian carcinoma: Final results of the phase 3, randomized, placebo-controlled ARIEL3 trial

Ledermann JA, Oza AM, Lorusso D, Aghajanian C, Oaknin A, Dean A, Colombo N, Weberpals JI, Clamp AR, Scambia G, Leary A, Holloway RW, Gancedo[...]